

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
August 5, 2009
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, August 5, 2009.

2. Welcome

Debbie Tapley, R.Ph. called the meeting to order and welcomed members, guests, and staff members.

Debbie Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Ed Behling, M.D.
Jody Bollinger, M.D.
Greg Browning, M.D.
Joe Horvath, M.D.

Kelly Jones, Pharm.D.
Jim Lindsay, M.D.
Thomas Phillips, R.Ph.
Tan Platt, M.D.

Charles Raine, M.D.
Debbie Tapley, R.Ph.
Edward Vess, R.Ph.
Harry Wright, M.D.

DHHS Staff Present:

Emma Forkner, Director
Marion Burton, M.D.
Mike Blakely, R.Ph.
Deidra Singleton, J.D.
Nikole Boland, J.D.

Other Representation:

First Health Services – Mary Roberts, R.Ph.
First Health Services – Bryan Amick, PharmD
Pharmaceutical Industry Speakers

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, May 6, 2009.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. SC DHHS Presentation

Director Forkner presented information regarding enrollment trends in the SC Medicaid population. Medicaid funding and the impact of the American Recovery and Reinvestment Act of 2009, as well as pending health reform legislation, were discussed.

C. Public Comment

The rules for public comment were outlined. Debbie Tapley instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

COMPANY	SPEAKER	DRUG
Glaxo Smith Kline	William F. Alleyne II, MD	Ventolin HFA®
Schering Plough Corporation	John F. Howard, PharmD	Proventil HFA®
Genzyme	Jeffrey W. Smith II, D.O.	Renvela®
Gilead Sciences, Inc.	Ali H. Toumadj, PharmD	Letairis®
Actelion Pharmaceuticals	Allison C. Widlitz, MS, PA-C	Tracleer®
Glaxo Smith Kline	William F. Alleyne II, MD	Advair®
AstraZeneca Pharmaceuticals	Matthew G. Marin, M.D., M.P.H.	Symbicort®
Alcon Laboratories	David J. Amrol, MD	Pataday®

D. Drug Classes for Review

Mary Roberts, R.Ph., First Health Services Corporation, led the discussion for the following drug classes:

- Beta Adrenergic Devices, Short Acting Inhalers
- Beta Adrenergic Agents, Short Acting Nebulizers
- Beta Blockers for Glaucoma
- Electrolyte Depleters
- Endothelin Receptor Antagonists
- Glucocorticoids and Long Acting Beta-2 Adrenergics
- Herpes Antivirals
- Ophthalmic Antihistamines

The following are the recommendations of the P & T Committee:

Beta Adrenergic Devices, Short Acting Inhalers

The Committee recommends that at least 1 agent in this class be preferred. Of the preferred agents, the Committee recommends that at least one (1) agent have a dose counter.

Beta Adrenergic Agents, Short Acting Nebulizers

Preferred

ALBUTEROL SULFATE

Non-Preferred

ACCUNEB®
ALBUTEROL (GENERIC ACCUNEB®)
METAPROTERENOL SULFATE
XOPENEX®

Beta Blockers for Glaucoma

Preferred

BETAXOLOL HCL
CARTEOLOL HCL
COMBIGAN®
LEVOBUNOLOL HCL
METIPRANOLOL
TIMOLOL MALEATE

Non-Preferred

AKBETA®
BETAGAN®
BETIMOL
BETOPTIC®
BETOPTIC S®
ISTALOL
OCUPRESS®
OPTIPRANOLOL
TIMOLOL MALEATE SOL-GEL
TIMOPTIC®
TIMOPTIC-XE®

Electrolyte Depleters

Preferred

PHOSLO®
RENAGEL®
FOSRENOL®
RENVELA®

Non-Preferred

ELIPHOS®
CALCIUM ACETATE

Endothelin Receptor Antagonists

Preferred

LETAIRIS®

Non-Preferred

TRACLEER®

Recommendation includes grandfathering patients on existing therapy.

Glucocorticoids and Long Acting Beta-2 Adrenergics

Preferred

ADVAIR DISKUS®
ADVAIR HFA®
SYMBICORT®

Non-Preferred

Herpes Antivirals

Preferred

ACYCLOVIR TAB/CAP
ACYCLOVIR SUSP
VALTREX®

Non-Preferred

FAMCICLOVIR
FAMVIR®
ZOVIRAX® TAB & CAPS
ZOVIRAX® SUSP

Ophthalmic Antihistamines

Preferred

ALAWAY OTC®
ZADITOR OTC®
KETOTIFEN OTC®
PATADAY®
PATANOL®
ELESTAT®

Non-Preferred

OPTIVAR®
EMADINE®
ZADITOR RX®

5. Old Business

The Committee was provided with information regarding safeguards against the use of Soriatane® by pregnant women. After discussion, the Committee recommended that Soriatane® be added as a preferred agent. The Committee also recommended that clinical edits be implemented to ensure that patients receiving Soriatane® therapy have the appropriate safeguards in place.

6. New Business

Mary Roberts presented an overview of the results of a pilot program aimed at improving the drug utilization and clinical outcomes of patients being treated for Hepatitis C.

7. Resolved Items

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS:

- Beta Adrenergic Devices, Short Acting Inhalers
- Beta Adrenergic Agents, Short Acting Nebulizers
- Beta Blockers for Glaucoma
- Electrolyte Depleters
- Endothelin Receptor Antagonists
- Glucocorticoids and Long Acting Beta-2 Adrenergics
- Herpes Antivirals
- Ophthalmic Antihistamines
- Soriatane®

8. Closing Comments

The next meeting will be held on Wednesday, August 5, 2009 at 4:00 p.m. at the same location.

9. Adjournment

The meeting adjourned at 6:30 PM